Physician profile
Eric K Magliulo
NPI 1336701689
$9,011.10
in general payments reported to CMS, 2019-2025
18 companies · $8,734 in 2025
The $8,734 reported for 2025 was more than what 95% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $85.52 · 2024: $192 · 2025: $8,734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,525 · Travel and Lodging: $2,033 · Food and Beverage: $1,350 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,525.00 |
| Travel and Lodging | $2,032.63 |
| Food and Beverage | $1,349.91 |
| Education | $103.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $8,080.38 | 2024-2025 | |
| Ani Pharmaceuticals, INC. | $208.90 | 2024-2025 | Purified Cortrophin Gel |
| Calliditas Therapeutics US INC. | $106.26 | 2023-2025 | Tarpeyo |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $103.56 | 2025 | |
| Fresenius USA Marketing, INC. | $94.83 | 2024-2025 | Velphoro, Velphoro |
| Travere Therapeutics, INC. | $62.65 | 2025 | |
| Vifor Pharma, INC. | $61.11 | 2024-2025 | Veltassa |
| Alexion Pharmaceuticals, INC. | $54.93 | 2024-2025 | Ultomiris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.81 | 2025 | Jardiance |
| Ascendis Pharma Endocrinology INC | $35.05 | 2025 | Yorvipath |
| Mallinckrodt Hospital Products INC. | $26.53 | 2025 | Acthar |
| Amgen INC. | $26.14 | 2025 | Krystexxa |
| Lilly USA, LLC | $22.30 | 2025 | Jardiance |
| Daiichi Sankyo INC. | $22.13 | 2025 | Injectafer |
| Scpharmaceuticals INC. | $18.99 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mozarc Medical US LLC | $17.25 | 2024 | Palindrome |
| Vantive US Healthcare LLC | $16.82 | 2025 | Renal - Pd |
| Bayer Healthcare Pharmaceuticals INC. | $13.46 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Magliulo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.